OverviewSuggest Edit

Aduro is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro’s three technology platforms are uniquely positioned to recruit and direct the immune system by activating cancer-fighting immune cells and inhibiting immune suppressive cells known to allow tumor growth.
Product candidates from Aduro’s LADD (live, attenuated double-deleted Listeria monocytogenes), STING Pathway Activators, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies (chemotherapy and radiation) as well as other cutting-edge immunotherapies. This diverse set of technology platforms has led to a strong pipeline of clinical and preclinical candidates, which are being evaluated in a number of cancer indications. Additionally, Aduro’s platforms have the potential to generate product candidates that address other therapeutic areas, such as autoimmune and infectious diseases.

TypePublic
Founded2000
HQBerkeley, CA, US
Websiteaduro.com
Employee Ratings4.2

Latest Updates

Employees (est.) (Dec 2018)152(-1%)
Revenue (FY, 2020)$827 K(-95%)
Share Price (Oct 2020)$14.6
Cybersecurity ratingBMore

Key People/Management at Aduro Biotech

Stephen T. Isaacs

Stephen T. Isaacs

Chairman, President and CEO
Andrea van Elsas

Andrea van Elsas

Chief Scientific Officer
Blaine Templeman

Blaine Templeman

Chief Administrative and Legal Officer
Dimitry S.A. Nuyten

Dimitry S.A. Nuyten

Chief Medical Officer
William G. Kachioff

William G. Kachioff

Interim Chief Financial Officer
Celeste Ferber

Celeste Ferber

Senior Vice President, General Counsel and Secretary
Show more

Aduro Biotech Office Locations

Aduro Biotech has offices in Berkeley and Oss
Berkeley, CA, US (HQ)
740 Heinz Ave
Oss, NL
9 Kloosterstraat
Oss, NL
Industrielaan 63
Show all (3)

Aduro Biotech Financials and Metrics

Aduro Biotech Revenue

Aduro Biotech's revenue was reported to be $827 k in FY, 2020
USD

Revenue (Q1, 2021)

351.0k

Net income (Q1, 2021)

(37.2m)

EBIT (Q1, 2021)

(37.1m)

Market capitalization (9-Oct-2020)

236.6m

Closing stock price (9-Oct-2020)

14.6

Cash (31-Mar-2021)

168.1m

EV

109.6m
Aduro Biotech's current market capitalization is $236.6 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

73.0m50.7m17.2m15.1m17.3m827.0k

Revenue growth, %

(31%)

General and administrative expense

27.8m34.3m33.8m36.0m34.8m19.1m

R&D expense

58.6m87.7m89.4m75.8m67.0m36.1m
Quarterly
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

150.5m74.9m157.6m126.3m59.6m187.8m

Accounts Receivable

4.8m1.1m989.0k12.0m342.0k262.0k

Prepaid Expenses

5.5m4.5m4.0m6.4m

Inventories

4.0m6.2m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(39.2m)(91.1m)(91.9m)(95.4m)(82.4m)(81.6m)

Depreciation and Amortization

634.0k2.0m4.0m5.0m554.0k422.0k

Inventories

349.0m260.0m

Accounts Payable

1.5m(2.9m)(1.2m)533.0k(799.0k)553.0k
USDQ1, 2015

Financial Leverage

-1.8 x
Show all financial metrics

Aduro Biotech Cybersecurity Score

Cybersecurity ratingPremium dataset

B

86/100

SecurityScorecard logo

Aduro Biotech Online and Social Media Presence

Embed Graph

Aduro Biotech News and Updates

Chinook Therapeutics Announces Update on Non-Renal Legacy Programs from Aduro Biotech Merger

Van Herk Investments to Form and Invest in Sairopa, a New Company Focused on Research and Development of B-Select Monoclonal Antibody Platform Programs

Aduro Biotech Stockholders Approve Merger Agreement with Chinook Therapeutics

One-for-Five Reverse Stock Split to be Effective October 2, 2020

Aduro Biotech Presents Nonclinical and Phase 1 Healthy Volunteer Data for BION-1301 at the 57th ERA-EDTA Virtual Congress

BERKELEY, Calif., June 02, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer, …

Aduro Biotech and Chinook Therapeutics Announce Definitive Merger Agreement

– Combined Company Will Operate as Chinook Therapeutics and Advance Pipeline of Clinical-Stage Programs in Kidney Diseases, Led by Atrasentan and BION-1301 in IgA Nephropathy

Aduro Biotech Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results

BERKELEY, Calif., March 09, 2020 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer,…

Aduro Biotech Announces First Patient Dosed in Phase 2 Study of ADU-S100 (MIW815) in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

BERKELEY, Calif., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer,…
Show more

Aduro Biotech Frequently Asked Questions

  • When was Aduro Biotech founded?

    Aduro Biotech was founded in 2000.

  • Who are Aduro Biotech key executives?

    Aduro Biotech's key executives are Stephen T. Isaacs, Andrea van Elsas and Blaine Templeman.

  • How many employees does Aduro Biotech have?

    Aduro Biotech has 152 employees.

  • What is Aduro Biotech revenue?

    Latest Aduro Biotech annual revenue is $827 k.

  • What is Aduro Biotech revenue per employee?

    Latest Aduro Biotech revenue per employee is $5.4 k.

  • Who are Aduro Biotech competitors?

    Competitors of Aduro Biotech include Codiak Biosciences, Jounce Therapeutics and Neovii.

  • Where is Aduro Biotech headquarters?

    Aduro Biotech headquarters is located at 740 Heinz Ave, Berkeley.

  • Where are Aduro Biotech offices?

    Aduro Biotech has offices in Berkeley and Oss.

  • How many offices does Aduro Biotech have?

    Aduro Biotech has 3 offices.